RHY.ASX: Appendix 4C and Market Update

Appendix 4C and Market Update

Stock	RHYTHM Biosciences Ltd (RHY.ASX)
Release Time	29 Oct 2025, 9:02 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Rhythm Biosciences Provides Quarterly Update

Key Points

Genetype secures two strategic distribution partnerships
Clinical study with University of Melbourne reaches 90%+ milestone
Strategic agreement with Memorial Sloan Kettering Cancer Center
ColoSTAT® achieves breakthrough clinical performance

Full Summary

Rhythm Biosciences Ltd (ASX:RHY), a transformative cancer diagnostics company, has released its business update and Appendix 4C for Q1 FY26. Key highlights include Genetype securing two strategic distribution partnerships, the clinical study with the University of Melbourne reaching a 90%+ milestone, a strategic agreement with Memorial Sloan Kettering Cancer Center, and ColoSTAT® achieving breakthrough clinical performance across all stages of colorectal cancer. The company also successfully raised $3.75m through an oversubscribed placement. Rhythm's CEO, Dr. David Atkins, commented that the strong start to FY26 positions the company to deliver on its strategic objectives for the year ahead. The company remains confident that FY26 will be a transformative year as it continues to execute its growth strategy and outperform internal expectations.

Guidance

Rhythm Biosciences expects FY26 revenue performance of Genetype to be well aligned to internal assumptions, on track to deliver significant quarter-on-quarter growth milestones.